Hatch Eyes Generic Biologics Bill Modeled On E.U. Approach

Law360, New York (October 10, 2004, 12:00 AM EDT) -- Senator Orrin Hatch is preparing legislation for generic biologics that would closely mirror existing European Union policy, according to sources.

The Utah Republican, who has crafted much of the most groundbreaking legislation on intellectual property policy in the U.S., has been meeting with executives in the drug and biotechnology industry to discuss his draft, expected to be introduced next congressional session.

The draft legislation would give companies 10 years of data exclusivity, compared to the three to five years under drug law.